4-tert-butyl-2-[2]furyl-thiazole | 100127-92-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4-tert-butyl-2-[2]furyl-thiazole
• 英文别名: 4-tert-Butyl-2-[2]furyl-thiazol；4-Tert-butyl-2-(furan-2-yl)-1,3-thiazole；4-tert-butyl-2-(furan-2-yl)-1,3-thiazole
• CAS: 100127-92-2
• 化学式: C₁₁H₁₃NOS
• 分子量: 207.296
• InChiKey: SPKNCFJBYZLITR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  54.3
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  1-mercapto-3,3-dimethyl-butan-2-one 在 氨 、 sulfur 作用下， 生成 4-tert-butyl-2-[2]furyl-thiazole
  参考文献：
  名称：

  Asinger et al., Justus Liebigs Annalen der Chemie, 1958, vol. 619, p. 145,157

  摘要：

  DOI：

文献信息

• COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE
  申请人：SHY Therapeutics LLC

  公开号：US20170174699A1

  公开（公告）日：2017-06-22

  Provided herein are compounds that inhibit the phosphorylation of MAPK and thus are useful in compositions and methods for treating cancer and inflammatory disease.

  本文提供了抑制MAPK磷酸化的化合物，因此可用于治疗癌症和炎症性疾病的组合物和方法。
• INHIBITORS OF MYOCARDIN-RELATED TRANSCRIPTION FACTOR AND SERUM RESPONSE FACTOR (MRTF/SRF)-MEDIATED GENE TRANSCRIPTION AND METHODS FOR USE OF THE SAME
  申请人：THE REGENTS OF THE UNIVERSITY OF MICHIGAN

  公开号：US20160145251A1

  公开（公告）日：2016-05-26

  Disclosed herein are inhibitors of gene transcription mediated by myocardin-related transcription factor and serum response factor, or both myocardin-related transcription factor and serum response factor (“MRTF/SRF”), and methods for their use in treating or preventing cancer and fibrosis. In particular, disclosed herein are compounds of Formula (I) and Formula (II), and pharmaceutically acceptable salts thereof: wherein the substituents are as described.

  本文披露了抑制由肌动蛋白相关转录因子和血清反应因子或肌动蛋白相关转录因子和血清反应因子（“MRTF / SRF”）介导的基因转录的抑制剂，以及它们在治疗或预防癌症和纤维化方面的使用方法。特别地，本文披露了公式（I）和公式（II）的化合物及其药学上可接受的盐：其中取代基如所述。
• Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
  申请人：SHY Therapeutics LLC

  公开号：US10588894B2

  公开（公告）日：2020-03-17

  Provided herein are methods and compositions for treating cancers, inflammatory diseases, rasopathies, and fibrotic disease involving aberrant Ras superfamily signaling through the binding of compounds to the GTP binding domain of Ras superfamily proteins including, in certain cases, K-Ras and mutants thereof, and a novel method for assaying such compositions.

  本文提供了通过化合物与 Ras 超家族蛋白（在某些情况下包括 K-Ras 及其突变体）的 GTP 结合结构域结合，治疗涉及 Ras 超家族信号异常的癌症、炎症性疾病、rasopathies 和纤维化疾病的方法和组合物，以及检测此类组合物的新方法。
• Inhibitors of myocardin-related transcription factor and serum response factor (MRTF/SRF)-mediated gene transcription and methods for use of the same
  申请人：THE REGENTS OF THE UNIVERSITY OF MICHIGAN

  公开号：US10662183B2

  公开（公告）日：2020-05-26

  Disclosed herein are inhibitors of gene transcription mediated by myocardin-related transcription factor and serum response factor, or both myocardin-related transcription factor and serum response factor (“MRTF/SRF”), and methods for their use in treating or preventing cancer and fibrosis. In particular, disclosed herein are compounds of Formula (I) and Formula (II), and pharmaceutically acceptable salts thereof: wherein the substituents are as described.

  本文公开了由心肌蛋白相关转录因子和血清反应因子或心肌蛋白相关转录因子和血清反应因子（"MRTF/SRF"）介导的基因转录抑制剂，以及将其用于治疗或预防癌症和纤维化的方法。特别是，本文公开了式(I)和式(II)化合物及其药学上可接受的盐： 其中的取代基如所述。
• Compounds for the treatment of cancer and inflammatory disease
  申请人：SHY Therapeutics LLC

  公开号：US10870657B2

  公开（公告）日：2020-12-22

  Provided herein are compounds that inhibit the phosphorylation of MAPK and thus are useful in compositions and methods for treating cancer and inflammatory disease.

  本文提供的化合物可抑制 MAPK 磷酸化，因此可用于治疗癌症和炎症性疾病的组合物和方法中。